Toni Choueiri: PEACE-3 phase 3 trials first results at ESMO24

Katy Beckermann, Assistant Professor Of Medicine, Vanderbilt University Medical Center, shared a post on X by Toni Choueiri adding:

“The RCC TiNivo-2 study may have been overall negative, but it highlighted:

1. CKI shouldn’t continue in IO-refractory disease.

2. Selective VEGF TKIs like tivozanib can have activity in the post-IO setting.

3. TKI dosage matters.”

Quoting Toni Choueiri’s post below:

“Outstanding talk from Silke Gillessen elegantly presenting PEACE-3 phase 3 trials first results.

Adding 6 cycles of Ra223 to enzalutamide as first-line therapy for mCRPC showed significant rPFS improvement and significant OS benefit.”

Source: Toni Choueiri/X and Katy Beckermann/X

Toni Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. He is the Medical Director of International Strategic Initiatives at Dana-Farber and past President of the Medical Staff at DFCI (2016-2018).